Tours

• An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent Recruiting
  2024-518289-28-00 4 2025-07-04 Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [I
• Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI). Recruiting
  2023-508132-65-00 4 2025-06-30 NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit … Recruiting
  2023-505834-84-00 10 2025-06-17 relapsed and refractory primary diffuse large B-cell lymphoma of the C
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• Randomized, controlled, multicenter Phase I/II study comparing the safety and immunogenicity of a booster dose of an intranasal COVID-19 vac … Recruiting
  2024-510589-17-00 7 2025-05-09 Healthy volunteers
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly Recruiting
  2024-513084-38-00 9 2025-04-15 Recently diagnosed non favorable Acute Myeloid Leukemias
• A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting
  2024-516363-92-00 5 2025-04-08 Psychosis Associated with Alzheimer’s Disease
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting
  2023-504904-26-00 5 2025-04-07 Progressive Pulmonary Fibrosis
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 Triple Negative Breast Cancer with residual disease after neoadjuvant
• Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting
  2023-509963-25-00 4 2025-01-17 Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting
  2023-506350-21-00 4 2025-01-06 Localized, resected, FIGO stage I (2018 classification), uterine leiom
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit … Recruiting
  2024-510981-18-00 5 2024-12-12 Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is o
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentr … Recruiting
  2023-508148-23-01 5 2024-12-02 chronically occluded coronary artery
• Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX Recruiting
  2024-510718-34-00 11 2024-11-29 Membranous nephropathy
• Multicentre randomised double-blind superiority trial with a roll-over phase to evaluate the efficacy of OM-89 vs placebo in reducing antibi … Recruiting
  2024-512595-35-00 5 2024-11-21 neurogenic bladder
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Acute non-severe osteomyelitis in children Recruiting
  2024-516744-26-00 4 2024-11-15 acute osteomyelitis of the child
• MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluati … Recruiting
  2024-515219-23-00 3 2024-11-08 multiple myeloma
• Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical … Recruiting
  2024-514886-21-00 6 2024-11-06 Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (P

Showing 121–144 of 320 trials